Guggenheim Capital LLC Corcept Therapeutics Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$21.97 - $33.8 $293,409 - $451,398	-13,355 Reduced 67.13%	6,540 $178,000
Q2 2023 Aug 11, 2023	SELL	$21.44 - $25.15 $270,508 - $317,317	-12,617 Reduced 38.81%	19,895 $442,000
Q1 2023 May 10, 2023	BUY	$19.2 - $24.47 $262,790 - $334,920	13,687 Added 72.71%	32,512 $704,000
Q4 2022 Feb 14, 2023	SELL	$19.95 - $29.96 $56,538 - $84,906	-2,834 Reduced 13.08%	18,825 $382,000
Q3 2022 Nov 14, 2022	SELL	$24.7 - $29.12 $9,114 - $10,745	-369 Reduced 1.68%	21,659 $555,000
Q2 2022 Aug 15, 2022	SELL	$17.33 - $25.3 $33,758 - $49,284	-1,948 Reduced 8.12%	22,028 $524,000
Q1 2022 May 16, 2022	BUY	$16.53 - $25.21 $34,977 - $53,344	2,116 Added 9.68%	23,976 $540,000
Q4 2021 Feb 14, 2022	SELL	$17.1 - $23.34 $720,252 - $983,080	-42,120 Reduced 65.83%	21,860 $433,000
Q3 2021 Nov 15, 2021	BUY	$19.68 - $22.53 $813,394 - $931,187	41,331 Added 182.48%	63,980 $1.26 Million
Q2 2021 Aug 13, 2021	SELL	$19.97 - $24.43 $30,374 - $37,158	-1,521 Reduced 6.29%	22,649 $498,000
Q1 2021 May 13, 2021	SELL	$23.49 - $30.56 $497,212 - $646,863	-21,167 Reduced 46.69%	24,170 $575,000
Q4 2020 Feb 16, 2021	BUY	$16.78 - $27.3 $588,373 - $957,247	35,064 Added 341.32%	45,337 $1.19 Million
Q3 2020 Nov 13, 2020	SELL	$12.46 - $19.98 $65,477 - $104,994	-5,255 Reduced 33.84%	10,273 $179,000
Q2 2020 Aug 14, 2020	BUY	$11.0 - $18.26 $170,808 - $283,541	15,528 New	15,528 $261,000
Q1 2020 Jun 02, 2020	SELL	$10.11 - $14.04 $175,095 - $243,158	-17,319 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $9,479 - $13,330	786 Added 4.75%	17,319 $210,000
Q3 2019 Nov 14, 2019	SELL	$10.41 - $14.66 $53,819 - $75,792	-5,170 Reduced 23.82%	16,533 $234,000
Q2 2019 Aug 14, 2019	SELL	$9.78 - $12.76 $124,959 - $163,034	-12,777 Reduced 37.06%	21,703 $242,000
Q1 2019 May 15, 2019	SELL	$10.03 - $15.71 $132,887 - $208,141	-13,249 Reduced 27.76%	34,480 $405,000
Q4 2018 Feb 14, 2019	SELL	$11.29 - $17.19 $666,663 - $1.02 Million	-59,049 Reduced 55.3%	47,729 $637,000
Q3 2018 Nov 14, 2018	BUY	$12.27 - $15.65 $223,755 - $285,393	18,236 Added 20.6%	106,778 $1.5 Million
Q2 2018 Aug 14, 2018	SELL	$15.3 - $19.69 $2.29 Million - $2.95 Million	-149,909 Reduced 62.87%	88,542 $1.39 Million
Q1 2018 May 15, 2018	BUY	$14.59 - $25.5 $398,657 - $696,762	27,324 Added 12.94%	238,451 $3.92 Million
Q4 2017 Feb 14, 2018	BUY	$15.77 - $20.72 $3.33 Million - $4.37 Million	211,127	211,127 $3.81 Million

Others Institutions Holding CORT

# of Institutions

368

Shares Held

86.8M

Call Options Held

1.12M

Put Options Held

667K

Black Rock Inc. New York, NY

16.5M
Shares

$1.13 Billion
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$689 Million
0.01% of portfolio
Ingalls & Snyder LLC New York, NY

8.1M
Shares

$552 Million
16.01% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

6.51M
Shares

$443 Million
0.48% of portfolio
Parallel Advisors, LLC

3.83M
Shares

$261 Million
4.44% of portfolio

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.29B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account